GSA Capital Partners LLP Lowers Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

GSA Capital Partners LLP trimmed its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 55.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,987 shares of the biopharmaceutical company’s stock after selling 13,465 shares during the quarter. GSA Capital Partners LLP’s holdings in TG Therapeutics were worth $257,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Marshall Wace LLP purchased a new stake in TG Therapeutics during the second quarter worth approximately $36,501,000. Principal Financial Group Inc. grew its stake in TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after buying an additional 725,371 shares during the period. Point72 Asset Management L.P. purchased a new stake in TG Therapeutics during the second quarter worth approximately $10,423,000. Assenagon Asset Management S.A. purchased a new stake in TG Therapeutics during the second quarter worth approximately $8,698,000. Finally, Point72 Europe London LLP purchased a new stake in TG Therapeutics during the second quarter worth approximately $2,860,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. The Goldman Sachs Group boosted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. HC Wainwright boosted their target price on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. B. Riley boosted their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, TD Cowen initiated coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $37.67.

Insider Buying and Selling at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares in the company, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 10.50% of the company’s stock.

TG Therapeutics Trading Up 1.5 %

Shares of TGTX stock opened at $35.07 on Friday. TG Therapeutics, Inc. has a 12 month low of $12.30 and a 12 month high of $36.50. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The business’s 50 day moving average is $25.62 and its two-hundred day moving average is $21.67. The company has a market cap of $5.46 billion, a PE ratio of -350.66 and a beta of 2.19.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company’s revenue was down 49.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.73 EPS. Equities analysts predict that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.